Heparin use itself can result in decreased antithrombin activity, an effect that is seen primarily with unfractionated heparin and not with low-molecular-weight heparin. 23 Among patients ...

Antithrombin, the principal physiological inhibitor of the blood coagulation proteinase thrombin, requires heparin as a cofactor. We report the crystal structure of the rate-determining encounter ...

Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III ...

July 7, 2004 -- Enoxaparin is noninferior to unfractionated heparin for the treatment of acute coronary syndromes (ACS), according to the results of two large studies published in the July 7 issue ...

For MATRIX Antithrombin, the investigators randomized 7,213 patients with STEMI (55.6%) or NSTE-ACS (44.4%) slated for PCI between October 2011 and November 2014 to receive either bivalirudin (n = ...

Causes of heparin resistance. Our main hypothesis was that, although rare, the heparin resistance could be secondary to an acquired antithrombin deficiency in the setting of severe sepsis,2 as ...

Low molecular weight heparin (LMWH) is an anticoagulant injected subcutaneously or intravenously and acts via activation of antithrombin III which in turn inactivates thrombin and factor Xa to ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

ATryn is a widely used drug for the treatment of antithrombin deficiency. The drug, developed by rEVO Biologics, received the U.S. Food and Drug Administration (FDA) approval in 2009. Antithrombin ...

Heparin regulates hemostasis at various points of the coagulation cascade mainly through its interaction with antithrombin and heparin cofactor II. Because of these properties, heparin is a ...